THERAPY DOSSIER · th-10240d4c8d1f

Astragaloside IV (purity 99.1 per cent), a saponin from Astragalus

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04026321 ↗PHASE1completed

Single-dose Escalation Study of SQ-001 Infusion Characterising PK of Astragaloside IV, Calycosin 7-O-beta-glucopyranoside and Lobetyolin

Solid Tumor Refractory to Standard Therapy

Enrolment: 40 · Results not recorded

NCT07382622 ↗NAcompleted

Effect of JointIQ on Joint Discomfort in Healthy Subjects

Joint Discomfort

Enrolment: 50 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26845156 ↗2016Reported benefit

Gastroprotective Effects of Astragaloside IV against Acute Gastric Lesion in Rats.

RatOtherSprague-DawleyMalen = 48 rats in total, six groups of eightIntragastric gavage1, 10 or 50 mg/kg body weight, suspended in 10 per cent Twe…Pre-treatment 1 h before water immersion and restraint stress

Model: Acute gastric lesion induced by water immersion and restraint stress for 12 h in Bollman-type cages at 20 degrees C after a 24 h fast

Astragaloside IV dose-dependently reduced gastric lesion area from 860.82 plus or minus 12.47 in the lesion control to 705.64 (1 mg/kg, 18.03 per cent inhibition), 499.41 (10 mg/kg, 41.26 per cent) and 251.48 (50 mg/kg, 70.79 per cent), comparable with omeprazole 20 mg/kg (270.58, 68.57 per cent).…

Extraction: extract · Supplied extraction confidence: 0.93. Machine-extracted fields require source verification.

Loading the evidence…